Edition:
United States

Neurosearch A/S (NEUR.CO)

NEUR.CO on Copenhagen Stock Exchange

4.09DKK
6:29am EDT
Change (% chg)

kr.-0.31 (-7.05%)
Prev Close
kr.4.40
Open
kr.4.35
Day's High
kr.4.39
Day's Low
kr.4.09
Volume
125,385
Avg. Vol
81,225
52-wk High
kr.5.20
52-wk Low
kr.2.80

Chart for

About

Neurosearch A/S (NEUR) is Denmark-based biopharmaceutical company. It specializes in the research, development and sale of drug candidates. The Company’s portfolio comprises three products: Tesofensine, a drug used in obesity, which works as a monoamine reuptake inhibitor (MRI); Seridopidine, which is applied in central nervous... (more)
No analyst recommendations are available for .

Overall

Beta: 0.17
Market Cap(Mil.): kr.108.04
Shares Outstanding(Mil.): 24.55
Dividend: --
Yield (%): --

Financials

  NEUR.CO Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -0.44 -- --
ROI: -14.99 -7.75 12.60
ROE: -14.99 -10.55 14.49

BRIEF-RegNeurosearch And Teva Pharmaceutical International Enter Into Agreement On Outstanding Obligations

* REG-NEUROSEARCH AND TEVA PHARMACEUTICAL INTERNATIONAL ENTER INTO AGREEMENT ON OUTSTANDING OBLIGATIONS

May 16 2018

BRIEF-Neurosearch: Gefion To Launch A Takeover Offer On Neurosearch

* RECEIVED A NOTICE FROM GEFION GROUP INVESTMENTS A/S THAT GEFION DECIDED TO LAUNCH A CONDITIONAL, VOLUNTARY TAKEOVER OFFER

Apr 27 2018

BRIEF-Neurosearch Says Is Investigating Potential Sale Of Company

* SAYS IS IN DISCUSSIONS WITH REGARD TO POTENTIAL SALE OF ITS RIGHTS TO PRIDOPIDINE FOR A SMALL SEVEN FIGURE AMOUNT IN DKK

Apr 19 2018

BRIEF-Neurosearch A/S FY Operating Loss Down to Dkk ‍1.0​ Million

* FY OPERATING LOSS DKK ‍1.0​ MILLION VERSUS LOSS DKK 6.3 MILLION YEAR AGO

Feb 09 2018

BRIEF-Neurosearch Contemplates Divestiture Of The Company

* ‍IS NOW AT A STAGE OF ITS RESOLUTION PLAN AT WHICH IT INTENDS TO EXPLORE POSSIBILITY OF DIVESTING COMPANY DURING COMING MONTHS​

Dec 05 2017

Earnings vs. Estimates

No consensus analysis data available.